Physician profile
Maxwell Su
NPI 1518461722
$4,880.36
in general payments reported to CMS, 2019-2025
18 companies · $781 in 2025
The $781 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $38.96 · 2021: $550 · 2022: $479 · 2023: $1,137 · 2024: $1,629 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,547.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,896.90 | 2019-2025 | Clareon, Ngenuity, Precision7 |
| Abbvie INC. | $719.53 | 2022-2025 | Durysta, Xen Glaucoma Treatment System |
| Glaukos Corporation | $447.24 | 2021-2025 | Photrexa Viscous and Photrexa, Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Sight Sciences, INC. | $418.47 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Biotissue Holdings INC. | $320.49 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $213.69 | 2022-2024 | Xiidra, Stellaris |
| New World Medical,INC. | $153.62 | 2019-2024 | Ahmed Glaucoma Valve, Streamline, Clearpath |
| Dompe US, INC. | $136.35 | 2024-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $117.53 | 2021 | |
| Oyster Point Pharma, INC. | $110.26 | 2022-2024 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $99.99 | 2019 | |
| Ocular Therapeutix, INC. | $68.45 | 2023-2024 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $38.96 | 2020 | |
| Amgen INC. | $37.83 | 2025 | Tepezza |
| Rayner Intraocular Lenses Limited | $35.17 | 2023 | Omidria, Rayone Aspheric, Rayone Emv |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $33.62 | 2025 | Xdemvy |
| Thea Pharma INC. | $19.12 | 2024 | Iyuzeh |
| Rxsight INC | $13.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxwell Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.